Definium Therapeutics DT120 Hits Primary Endpoint in GAD Phase 3

Definium Therapeutics (DFTX) said its Phase 3 Voyage study of DT120 ODT met the primary endpoint in generalized anxiety disorder, sending shares up in early trading.

The trial randomized patients to either DT120 or placebo. The drug hit statistical significance on the Hamilton Anxiety Rating Scale at week 8, the company said. Definium plans to file for FDA approval in the first half of 2027.

CEO Rob Barrow called the results "unprecedented" on a call with analysts Tuesday morning. He did not provide specific effect-size data on the call but said the company would present full results at a future medical meeting.

The safety profile was consistent with earlier studies, with no new signals, Chief Medical Officer Dan Karlin said. The most common side effects were mild somnolence and headache, both in line with the known profile of the drug class.

GAD affects roughly 6 million adults in the U.S. annually, and current standard-of-care options include SSRIs and SNRIs, which can take weeks to work and come with side effects like sexual dysfunction. DT120 is a sublingual formulation of a GABA-A receptor modulator designed for faster onset.

Several analysts on the call pressed for more granular efficacy data. Marc Goodman at Leerink asked whether the separation from placebo was consistent across subgroups. Karlin said the signal was robust in both high- and low-baseline severity groups but declined to give numerical breakdowns before the formal presentation.

The stock has run up about 40% over the past six months on anticipation of this readout. Definium had about $320 million in cash at the end of the second quarter, enough to fund the NDA submission and launch prep without a near-term raise, CFO Brandi Roberts said.

Jefferies analyst Lin Tsai, who rates the stock a buy, said the topline hit removes the binary risk but that investors will need to see the full dataset to gauge commercial potential. "The 8-week primary endpoint is standard for GAD, but durability and functional outcomes matter for pricing discussions," he said on the call.

Definium's Alpha Score sits at 57 out of 100, a "Moderate" label, according to AlphaScala's stock market analysis. The WFC stock page and RBC stock page track peers in the sector.

Barrow declined to comment on pricing strategy but said the company has begun manufacturing scale-up for commercial supply. The next catalyst is the full data presentation at a medical conference, likely in the first quarter of 2027.